ASCO 2023: Global study finds simple hysterectomy a safe option for people with early-stage, low-risk cervical cancer
“For patients with stage 1 cervical cancer who are eligible for surgery, radical hysterectomy has…
Browsing: ASCO
ASCO 2023: Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel
Chemotherapy-induced peripheral neuropathy (CIPN) – nerve pain, tingling, or numbness in the hands or feet…
ASCO 2023: Osimertinib after surgery significantly improves survival in patients with resected EGFR-mutated non-small cell lung cancer
Treatment with osimertinib after surgery significantly lowered the risk of death in adults with completely…
ASCO 2023: Study may provide clues to treating colorectal cancer more effectively in younger patients
While the incidence of colorectal cancer (CRC) has dropped significantly among older adults in recent…
ASCO 2023: Phase 3 trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy
A phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma…
ASCO 2023: Thyroid cancer precision approaches that incorporate targeted therapies and other treatments are changing the surgeon’s role
Historically, surgery was the first line of treatment for patients with thyroid cancer. Now, as…
ASCO 2023: Immunotherapy for brain cancer metastases shows clinical benefit
In a phase 2 clinical trial of the immune checkpoint inhibitor pembrolizumab, investigators found that…
ASCO 2023: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center…
ASCO 2023: Antibody-microtubule inhibitor conjugate improves survival in women with recurrent ovarian cancer
MIRASOL, an international phase III randomised clinical trial, found that mirvetuximab soravtansine, an antibody and…
ASCO 2023: Trastuzumab deruxtecan effectively treats HER2-expressing cancers regardless of tumour location
Trastuzumab deruxtecan (marketed as Enhertu) is an effective treatment option for people with difficult-to-treat HER2-expressing…